Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE

European Journal of Haematology

Volumn 81, Issue 6, 2008, Pages 432-436

  Srikanth, Muralikrishnan ^a   Davies, Faith E ^a   Wu, Ping ^a   Jenner, Matthew W ^a   Ethell, Mark E ^a   Potter, Michael N ^a   Shaw, Bronwen E ^a   Saso, Radovan M ^a   Dines, Sharon ^a   Morgan, Gareth J ^a,b  

^a Royal Marsden Hospital   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Blastoid myeloma; DT PACE; Extramedullary myeloma; Multiple myeloma

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; BORTEZOMIB; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CELL CYCLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; FEBRILE NEUTROPENIA; GRANULOCYTIC SARCOMA; HUMAN; MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RELAPSE; SURVIVAL; THERAPY EFFECT; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 56649121688     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01131.x     Document Type: Article

References (19)

1. Greipp PR, Raymond NM, Kyle RA, et al. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985 65 : 305 10.
2. Carter A, Hocherman I, Linn S, et al. Prognostic significance of plasma cell morphology in multiple myeloma. Cancer 1987 60 : 1060 5.
3. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology - an independent prognostic factor with clinical and laboratory corelates: Eastern Cooperative Oncology Group(ECOG) myeloma trial E9486 report by the ECOG Myeloma laboratory group. Blood 1998 91 : 2501 7.
4. Rajkumar V, Fonseca R, Lacy MQ, et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem cell transplantation for multiple myeloma. J Clin Oncol 1999 17 : 1551 7.
5. Ribas C, Colleoni GW, Almeida MS, et al. Plasmablastic multiple myeloma is associated with increased vascular endothelial growth factor immunoexpression. Braz J Med Biol Res 2005 8 : 1609 13.
6. D'Amato RJ, Loughman MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proct Natl Acad Sci USA 1994 91 : 4082 5.
7. Barlogie B, Velasquez WS, Alexanian R, et al. Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicin and dexamethasone refractory myeloma. J Clin Oncol 1989 10 : 1514 7.
8. Desikan KR, Jagannath S, Seigel D, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP) for relapsed refractory myeloma. J Buon 2007 12 : 41 4.
9. Lee CK, Barlogie B, Munshi N, et al. DT-PACE: an effective, novel combination chemotherapy with thalidomide for previously treated myeloma patients. J Clin Oncol 2003 21 : 2732 9.
10. Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008 140 : 625 34.
11. Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006 91 : 141 2.
12. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European group for Blood and Marrow Transplant. Br J Haematol 1998 102 : 1115 23.
13. Damaj D, Mohty N, Vey E, et al. Features of extramedullary and extraosseous multiple myeloma: report of 19 patients from a single centre. Eur J Haematol 2004 73 : 402 6.
14. Rosinol L, Cibeira T, Uriburu C, et al. Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006 76 : 405 8.
15. Biaggi JJ, Mileshkin L, Grigg AP, et al. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogenic transplantation. Bone Marrow Transplant 2001 28 : 1145 50.
16. Blade J, Perales M, Rosinol L, et al. Thalidomide in multiple myeloma: lack of response of soft tissue plasmacytomas. Br J Haematol 2001 113 : 422 4.
17. Myers B, Grimley C, Crouch D, et al. Lack of response to thalidomide in plasmacytomas. Br J Haematol 2001 115 : 234.
18. Anagnostopoulous A, Hamilos G, Zorzou MP, et al. Discordant response or progression in patients with myeloma treated with thalidomide based regimens. Leuk Lymphoma 2004 45 : 113 6.
19. Wang M, Delaskalle K, Giralli S, et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005 106 : 231a.